Skip to content

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00974610
Enrollment
803
Registered
2009-09-10
Start date
2008-08-31
Completion date
2017-01-31
Last updated
2017-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer

Keywords

stage IV melanoma, recurrent melanoma, stage IV non-small cell lung cancer, recurrent non-small cell lung cancer, extensive stage small cell lung cancer, recurrent small cell lung cancer, stage IV breast cancer, recurrent breast cancer, male breast cancer, stage III pancreatic cancer, stage IV pancreatic cancer, recurrent pancreatic cancer, stage IV colon cancer, recurrent colon cancer, stage IV rectal cancer, recurrent rectal cancer

Brief summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

Detailed description

OBJECTIVES: Primary * To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups. Secondary * To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy. OUTLINE: This is a multicenter study. Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.

Interventions

None listed

Sponsors

Cancer Trials Ireland
Lead SponsorNETWORK

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following advanced metastatic malignancies: * Malignant melanoma * Lung cancer * Breast cancer * Pancreatic carcinoma * Colorectal cancer * Advanced and/or metastatic disease * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

MeasureTime frame
Detection of peptide and protein markers in serumOngoing

Secondary

MeasureTime frame
Identification of the protein/peptide involvedOngoing

Countries

Ireland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026